Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24weeks
Just $1.99 per week for the first 24weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);

Cannabis Professional’s daily roundup of industry news. View archive here.

Canopy appoints new board chair, board member

Canopy Growth Corp. has appointed a new chair for its board of directors and added another member to the board, the company said Wednesday. Judy Schmeling will take over as chairman — a position recently vacated by David Klein, who became Canopy’s CEO in December.

Ms. Schmeling has been on Canopy’s board since November 2018, and she also sits on the board of Canopy’s main backer, Constellation Brand Inc. as well as on the board of Casey’s General Stores. She is the former chief operating officer of online retailer HSN Inc.

Story continues below advertisement

Jim Sabia, another Constellation executive, has also joined Canopy’s board. Mr. Sabia currently serves as Constellation’s chief marketing officer, and was previously vice president of marketing and media at Molson Coors Brewing Co.

“Mr. Sabia will act as an observer to the board as he and Canopy complete the standard Health Canada processes associated with the appointment,” Canopy said in a statement.

– Mark Rendell

Second Aphria facility receives EU GMP certification

A second Aphria Inc. facility has received European Union Good Manufacturing Practices (EU GMP) certification. The company’s Aphria One facility in Leamington, Ont. has been certified by Malta’s health authority as “an active substance manufacturer,” the company said on Wednesday.

The announcement comes a day after Aphria announced that its subsidiary ARA - Avanti Rx Analytics received EU GMP certification. Having EU GMP certification is a prerequisite for shipping cannabis to most European Union countries.

“The certification will allow the Company’s Aphria One facility to be a supplier of bulk dried flower for medicinal use worldwide to other EU GMP certified facilities licensed to further process or package bulk dried flower into finished cannabis product for sale in permitted jurisdictions,” Aphria said in a statement.

- Mark Rendell

Story continues below advertisement

Recently, around the industry:

Related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies